A mathematical approach for evaluating the influence of dose heterogeneity on TCP for prostate cancer brachytherapy treatment

Physics in Medicine and Biology
Lidia StrigariMarcello Benassi

Abstract

The low-dose-rate brachytherapy technique has proven suitable for the management of prostate cancer. However, published data generally report the clinical outcome and the minimum peripheral dose (mPD) to the target volume and not the actual dose distribution in patients. To this end, modern guidelines recommend the use of specific dose and volume indices describing dose distribution throughout the target. The introduction of a method, based on the standard linear quadratic model and Poisson statistics, entitled the F-factor allows the TCP from different DVHs to be calculated, by using the TCP from a uniform dose distribution as the reference. The F-factor sensitivity against radiobiological parameters and influence of the DVH were evaluated. We applied the F-formula on the post-plan DVHs of 58 patients treated with (125)I permanent seed implant brachytherapy for localized prostate cancer. F shows a strong correlation with dosimetric parameters already reported as significant predictors of the biochemical outcome.

References

Dec 1, 1992·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·H SuitJ T Efird
Mar 1, 1988·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·J DutreixA Dutreix
Jul 1, 1987·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·P Scalliet, A Wambersie
Jan 1, 1987·Acta Oncologica·A Brahme, A K Agren
Apr 1, 1986·International Journal of Radiation Oncology, Biology, Physics·M Goitein
Aug 1, 1985·International Journal of Radiation Oncology, Biology, Physics·M Goitein, T E Schultheiss
May 15, 1995·International Journal of Radiation Oncology, Biology, Physics·C C LingL L Anderson
Jan 15, 1994·International Journal of Radiation Oncology, Biology, Physics·L BegnozziM Benassi
Oct 1, 1996·Physics in Medicine and Biology·R G Dale
Oct 1, 1996·International Journal of Radiation Oncology, Biology, Physics·C S WuuH I Amols
Mar 15, 1997·International Journal of Radiation Oncology, Biology, Physics·K M HaustermansJ F Fowler
May 20, 1998·International Journal of Radiation Oncology, Biology, Physics·R G StockJ K DeWyngaert
Mar 17, 1999·International Journal of Radiation Oncology, Biology, Physics·R G Dale, B Jones
Apr 7, 1999·International Journal of Radiation Oncology, Biology, Physics·D J Brenner, E J Hall
Jul 1, 1999·International Journal of Radiation Oncology, Biology, Physics·G M Duchesne, L J Peters
Aug 19, 2000·International Journal of Radiation Oncology, Biology, Physics·K Hausterman, J F Fowler
Jun 8, 2001·International Journal of Radiation Oncology, Biology, Physics·L PottersX H Wang
Jun 29, 2001·International Journal of Radiation Oncology, Biology, Physics·J FowlerM Ritter
Aug 23, 2001·International Journal of Radiation Oncology, Biology, Physics·W D D'Souza, H D Thames
Apr 17, 2002·International Journal of Radiation Oncology, Biology, Physics·Roger G Dale, Bleddyn Jones
Jun 21, 2002·European Urology·Richard G Stock, Nelson N Stone
Dec 31, 2002·International Journal of Radiation Oncology, Biology, Physics·Jian Z WangX Allen Li
Sep 6, 2003·International Journal of Radiation Oncology, Biology, Physics·Alan E NahumJ Donald Chapman
Oct 1, 2003·Physics in Medicine and Biology·X Allen LiSteven J DiBiase
Apr 7, 2004·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·P MangiliB Longobardi
Jun 12, 2004·Medical Physics·Marco CarlonePeter Raaphorst
Sep 28, 2004·Physics in Medicine and Biology·Annette HaworthGillian Duchesne
Jul 29, 2006·Medical Physics·Lidia StrigariMarcello Benassi
Aug 4, 2006·The British Journal of Radiology·J Z WangN A Mayr
Nov 7, 2006·International Journal of Radiation Oncology, Biology, Physics·Michael J ZelefskyEric M Horwitz
Dec 26, 2006·International Journal of Radiation Oncology, Biology, Physics·Michael J ZelefskyMarco Zaider

❮ Previous
Next ❯

Citations

May 4, 2013·European Journal of Nuclear Medicine and Molecular Imaging·Francesca BottaGiovanni Paganelli
Jun 12, 2014·European Journal of Nuclear Medicine and Molecular Imaging·Lidia StrigariGlenn Flux
Jul 10, 2014·International Journal of Radiation Biology·Michael J Balderson, Charles Kirkby

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.